Cardiovascular Systems Inc. (NASDAQ:CSII) SVP Paul A. Koehn sold 30,910 shares of Cardiovascular Systems stock in a transaction that occurred on Monday, October 10th. The shares were sold at an average price of $25.07, for a total transaction of $774,913.70. Following the transaction, the senior vice president now directly owns 110,200 shares in the company, valued at approximately $2,762,714. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Cardiovascular Systems (NASDAQ:CSII) last released its quarterly earnings results on Wednesday, August 3rd. The medical device company reported ($0.15) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.05. Cardiovascular Systems had a negative net margin of 31.44% and a negative return on equity of 38.39%. The business had revenue of $48.50 million for the quarter, compared to analysts’ expectations of $46.01 million. During the same period last year, the business earned ($0.27) EPS. The company’s revenue was up .0% compared to the same quarter last year.

Insider Buying and Selling by Quarter for Cardiovascular Systems (NASDAQ:CSII)

Hedge funds have recently added to or reduced their stakes in the stock. Wellington Management Group LLP boosted its stake in Cardiovascular Systems by 27.6% in the first quarter. Wellington Management Group LLP now owns 3,018,859 shares of the medical device company’s stock worth $31,306,000 after buying an additional 652,962 shares in the last quarter. Vanguard Group Inc. boosted its stake in Cardiovascular Systems by 13.8% in the second quarter. Vanguard Group Inc. now owns 1,276,110 shares of the medical device company’s stock worth $23,449,000 after buying an additional 155,207 shares in the last quarter. BlackRock Fund Advisors boosted its stake in Cardiovascular Systems by 7.4% in the second quarter. BlackRock Fund Advisors now owns 1,029,274 shares of the medical device company’s stock worth $18,913,000 after buying an additional 70,775 shares in the last quarter. BlackRock Institutional Trust Company N.A. boosted its stake in Cardiovascular Systems by 6.8% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 805,778 shares of the medical device company’s stock worth $14,806,000 after buying an additional 51,329 shares in the last quarter. Finally, FMR LLC boosted its stake in Cardiovascular Systems by 24.0% in the second quarter. FMR LLC now owns 620,000 shares of the medical device company’s stock worth $11,393,000 after buying an additional 120,000 shares in the last quarter. Institutional investors and hedge funds own 68.16% of the company’s stock.

Several equities analysts have weighed in on the stock. JMP Securities assumed coverage on shares of Cardiovascular Systems in a report on Friday, October 7th. They set an “outperform” rating and a $35.00 price target on the stock. Zacks Investment Research raised shares of Cardiovascular Systems from a “hold” rating to a “buy” rating and set a $27.00 price target on the stock in a report on Tuesday, October 4th. Leerink Swann raised shares of Cardiovascular Systems from a “market perform” rating to an “outperform” rating and set a $30.00 price target on the stock in a report on Monday, August 22nd. Bank of America Corp. raised shares of Cardiovascular Systems from an “underperform” rating to a “neutral” rating in a report on Thursday, August 4th. Finally, Needham & Company LLC lifted their price target on shares of Cardiovascular Systems from $23.00 to $27.00 and gave the company a “buy” rating in a report on Thursday, August 4th. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $27.40.

About Cardiovascular Systems

Cardiovascular Systems, Inc is a medical technology company. The Company is engaged in treating patients suffering from peripheral and coronary arterial diseases. It has developed an orbital atherectomy technology for peripheral and coronary commercial applications. Its peripheral arterial disease systems are catheter-based platforms that treat plaque types in leg arteries both above and below the knee.

5 Day Chart for NASDAQ:CSII

Receive News & Stock Ratings for Cardiovascular Systems Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiovascular Systems Inc. and related stocks with our FREE daily email newsletter.